Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of atogepant for prevention of menstrual migraine
2024-512946-41-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Catamenial Migraine comparing Atogepant with Placebo (2 arms). Primary endpoint: Change from baseline in number of migraine days during the perimenstrual period. Planned start Mar 2025; status: authorised.
02
Drugs
atogepant
03
Conditions
Catamenial Migraine
Beyond the preview
Go deeper on 2024-512946-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512946-41-00.